Annals of Surgical Oncology Surgery

An International Randomized Prospective Trial Comparing a Supine MRI-based Guidance System, The Breast Cancer LocatorTM, to Wire Localization for Breast-Conserving Surgery for Non-palpable Breast Cancer

Jennifer S. Gass, Sarah Pesek, Brian Czerniecki, Jessica Ryan, David Edmonson, Wey-Liang Leong, Jamie Patterson, Winne Polen, H. E. Guy Burman, Laila Samiian, Rebecca Kwait, Richard Ehlers, Kelly Hunt, Abigail Madans, Bret Taback, Kari Rosenkranz, Karen Ching-Tismal, James Harvey, Catherine Akay, Boris Bronfine, Nazanin Khakpour, Abhishek Chatterjee, Angelika Wolfrum, Sumohan Chatterjee, William Diehl, Lucinda Guerra, Kerry Bennett, Suzanne Coopey, Sommer Gunia, Stacey Abbis, Gabriel Kaufman, Andrew Loehrer, Abdalla Saad Abdalla Al-Zawi, Susie X Sun, Rajiv Dave, Ryan Deisler, Micaela Weaver, D. Wayne Chicken, Constanza Cocilovo, Urvashi Jain, Sharita Nagaraj, Sarah Persing, Jennifer Tonneson, Burghard Abendstein, Shawna Willey, Timothy Rooney, Helene Cauwel-Schryve, Misty Fox, Venkataramanan Krishnaswamy, Keith Paulsen, Richard J. Barth
Springer Nature · 2026-10-22 · DOI 10.1245/s10434-026-20657-6

Abstract

Abstract Background Positive margins after breast-conserving surgery (BCS) require additional surgery, a negative patient experience that also adds costs to care. Pilot trials indicate the Breast Cancer Locator TM (BCL), a novel supine magnetic resonance imaging–based guidance system, helps surgeons resect cancers with a low positive margin rate (PMR). Our objective was to evaluate BCL noninferiority and superiority compared with wire localization (WL) in reducing the PMR with BCS. Methods Patients with nonpalpable, magnetic resonance imaging–visualized invasive breast cancer or ductal carcinoma in situ undergoing BCS were prospectively randomized to either BCL or WL. Results In total, 418 randomized patients underwent surgery. The PMR was 14.4% (30/209) in the BCL group and 21.1% (44/209) in the WL group, a relative decrease of 32%. In primary analysis, the treatment difference was −7.1% (95.4% confidence interval [CI] −14.3 to 0.1). Noninferiority was demonstrated ( p = 0.011). The one-sided p -value for superiority ( p = 0.025) slightly exceeded the prespecified significance level of 0.023. In prespecified analysis stratified by final tumor type, the PMR was significantly lower in the BCL group ( p = 0.019). Fewer BCL patients underwent re-excision: 12.9% versus 19.6%, a relative decrease of 34%. The PMR for all tumor types was lower in the BCL group, with a > 60% relative reduction in PMR in patients with ductal carcinoma in situ (20.6% vs. 53.3% [95% CI −52.1 to −9.1]) and invasive lobular carcinoma (9.1% vs. 25.6% [95% CI −32.9 to −0.2]). Adverse event rates were similar. Conclusions BCL was noninferior to WL and superior in analysis stratified by final tumor type. Clinically meaningful relative reductions in PMR and re-excision rates were observed.

Read at publisher →